Anheuser-Busch InBev, the world’s largest brewer, was hit with an EU antitrust fine of €200 million (US$225 million) on Monday, May 13, for preventing cheaper beer imports from the Netherlands into Belgium, reported the Financial Times.
The European Commission’s decision came after a three-year investigation into the brewer’s most popular brand in Belgium, Jupiler, which has a 40% market share. Reuters reported last July that the company would be penalized.
“Consumers in Belgium have been paying more for their favorite beer because of AB InBev’s deliberate strategy to restrict cross border sales between the Netherlands and Belgium,” EU Competition Commissioner Margrethe Vestager said.
Headquartered in Leuven, AB InBev has held more than 50% share of the beer market in its home country for nearly a quarter of a century. Jupiler is its most popular brand in Belgium and represents around 40% per cent of the total Belgian beer sold domestically by volume, according to the Commission. EU officials determined that the company is dominant in the market for Belgian beer — based on high market share, its ability to increase prices, and “significant” barriers to entry.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Live Nation Under Criminal Antitrust Investigation Over Pandemic-Era Refund Policies
May 19, 2025 by
CPI
BCLP Strengthens Healthcare and Antitrust Litigation Practice
May 19, 2025 by
CPI
Italy Fines AI Chatbot Maker Replika €5 Million Over Privacy Violations
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas